Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3288-3297

  Salman, Sam ^a   Page Sharp, Madhu ^b   Batty, Kevin T ^b   Kose, Kaye ^c   Griffin, Susan ^c   Siba, Peter M ^c   Ilett, Kenneth F ^a   Mueller, Ivo ^c   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEQUICK; DIHYDROARTEMISININ PLUS PIPERAQUINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALARIA; MALE; MASS SPECTROMETRY; PARASITE CLEARANCE; PARASITEMIA; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; RECURRENT INFECTION;

ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALARIA; MALE; QUINOLINES;

EID: 84861141952     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06232-11     Document Type: Article

References (49)

1. Ahmed T, et al. 2008. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J. Clin. Pharmacol. 48:166-175.
2. Alin MH, Ashton M, Kihamia CM, Mtey GJ, Bjorkman A. 1996. Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Br. J. Clin. Pharmacol. 41:587-592. (Pubitemid 26184681)
3. Anderson BJ, Holford NH. 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24:25-36.
4. Annerberg A, et al. 2011. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob. Agents Chemother. 55:3971-3976.
5. Ashley EA, et al. 2007. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop. Med. Int. Health 12:195-200.
6. Ashton M, et al. 1998. Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. Biopharm. Drug Dispos. 19:245-250. (Pubitemid 28218419)
7. Ashton M, et al. 1998. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab. Dispos. 26:25-27. (Pubitemid 28071320)
8. Barnes KI, et al. 2006. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80:582-596. (Pubitemid 44920218)
9. Batty KT, et al. 1996. Selective high-performance liquid chromatographic determination of artesunate and alpha- and beta-dihydroartemisinin in patients with falciparum malaria. J. Chromatogr. B Biomed. Appl. 677:345-350. (Pubitemid 26106005)
10. Benakis A, Paris M, Loutan L, Plessas CT, Plessas ST. 1997. Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am. J. Trop. Med. Hyg. 56:17-23. (Pubitemid 27097953)
11. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Predictioncorrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13:143-151.
12. Bönsch C, et al. 2010. Chloroquine and its derivatives exacerbate B19Vassociated anemia by promoting viral replication. PLoS Negl. Trop. Dis. 4:e669.
13. Cattani JA, et al. 1986. The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am. J. Trop. Med. Hyg. 35:3-15. (Pubitemid 16140830)
14. Chinh NT, et al. 2009. Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob. Agents Chemother. 53:828-831.
15. Crauwels HM, et al. 2010. Relative bioavailability of a concept paediatric formulation of TMC278, an investigational NNRTI. Abstr. 18th Int. AIDS Soc. Conf., abstr THPE0158.
16. Denis MB, et al. 2002. Efficacy and safety of dihydroartemisininpiperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin. Infect. Dis. 35:1469-1476.
17. Djimdé AA, et al. 2003. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 69:558-563. (Pubitemid 38248261)
18. Dondorp AM, et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
19. Duc DD, et al. 1994. The pharmacokinetics of a single dose of artemisinin in healthy Vietnamese subjects. Am. J. Trop. Med. Hyg. 51:785-790.
20. European Medicines Agency. 2011. Eurartesim. http://www.ema.europa.eu/ docs/en-GB/document-library/Summary-of-opinion---Initial-authorisation/human/ 001199/WC500108010.pdf. Accessed September 1, 2011.
21. Gordi T, Hai TN, Hoai NM, Thyberg M, Ashton M. 2000. Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin. Eur. J. Clin. Pharmacol. 56:561-566.
22. Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M. 2002. Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob. Agents Chemother. 46:1026-1031. (Pubitemid 34260346)
23. Gordi T, et al. 2005. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br. J. Clin. Pharmacol. 59:189-198. (Pubitemid 40208855)
24. Gordi T, Xie R, Jusko WJ. 2005. Semi-mechanistic pharmacokinetic/ pharmacodynamic modelling of the antimalarial effect of artemisinin. Br. J. Clin. Pharmacol. 60:594-604. (Pubitemid 41705378)
25. Hai TN, Hietala SF, Van Huong N, Ashton M. 2008. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop. 107:145-149.
26. Hassan Alin M, Ashton M, Kihamia CM, Mtey GJ, Bjorkman A. 1996. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans. R. Soc. Trop. Med. Hyg. 90:61-65. (Pubitemid 26069449)
27. Hasugian AR, et al. 2007. Dihydroartemisinin-piperaquine versus artesunate- amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin. Infect. Dis. 44:1067-1074. (Pubitemid 46580274)
28. Hung TY, et al. 2004. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57:253-262.
29. Karunajeewa HA, et al. 2008. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob. Agents Chemother. 52:237-243.
30. Krudsood S, et al. 2007. Dose ranging studies of new artemisininpiperaquine fixed combinations compared to standard regimens of artemisisnin combination therapies for acute uncomplicated falciparum malaria. Southeast Asian J. Trop. Med. Public Health 38:971-978.
31. Liu C, et al. 2007. Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers. Yakugaku Zasshi 127:1709-1714. (Pubitemid 47511076)
32. Matuszewski BK, Constanzer ML, Chavez-Eng CM. 2003. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75:3019-3030. (Pubitemid 36830428)
33. Mwesigwa J, et al. 2010. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob. Agents Chemother. 54:52-59.
34. Nguyen TC, et al. 2008. Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am. J. Trop. Med. Hyg. 79:620-623.
35. Porter CJ, Trevaskis NL, Charman WN. 2007. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6:231-248. (Pubitemid 46344627)
36. Price RN, et al. 2007. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drugresistant malaria. Antimicrob. Agents Chemother. 51:4090-4097. (Pubitemid 350057809)
37. Pyar KP, Myint WW, Kyaw MP, Zin T, Than M. 2009. Efficacy and safety of artemisinin-piperaquine (Artequick) compared to dihydroartemisinin-piperaquine (Artekin) in uncomplicated falciparum malaria in adults. Myanmar Health Sci. Res. J. 21:78-82.
38. Röshammar D, Hai TN, Friberg Hietala S, Van Huong N, Ashton M. 2006. Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur. J. Clin. Pharmacol. 62:335-341.
39. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726. (Pubitemid 47477040)
40. Sidhu JS, et al. 1998. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 45:347-354. (Pubitemid 28138826)
41. Sim IK, Davis TM, Ilett KF. 2005. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob. Agents Chemother. 49: 2407-2411. (Pubitemid 40734473)
42. Svensson US, Alin H, Karlsson MO, Bergqvist Y, Ashton M. 2002. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur. J. Clin. Pharmacol. 58:339-351. (Pubitemid 34983925)
43. Svensson US, et al. 1998. Artemisinin induces omeprazole metabolism in human beings. Clin. Pharmacol. Ther. 64:160-167. (Pubitemid 28423851)
44. Tarning J, et al. 2008. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 52:1052-1061. (Pubitemid 351358388)
45. Tarning J, et al. 2005. Pitfalls in estimating piperaquine elimination. Antimicrob. Agents Chemother. 49:5127-5128. (Pubitemid 41778931)
46. Trung TN, Tan B, Van Phuc D, Song JP. 2009. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. Chin. J. Integr. Med. 15:189-192.
47. World Health Organization Communicable Diseases Cluster. 2000. Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl. 1):S1-S90.
48. World Health Organization. 2010. Guidelines for the treatment of malaria - 2nd ed. World Health Organization, Geneva, Switzerland.
49. Zwang J, et al. 2009. Safety and efficacy of dihydroartemisininpiperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 4:e6358.